KalVista Pharmaceuticals, Inc.
KALV · NASDAQ
9/30/2025 | 7/31/2025 | 4/30/2025 | 1/31/2025 | |
|---|---|---|---|---|
| Market Cap | – | $729,166 | $683,720 | $469,012 |
| - Cash | $243,497 | $124,304 | $98,644 | $167,288 |
| + Debt | $148,156 | $6,141 | $6,307 | $5,782 |
| Enterprise Value | – | $611,003 | $591,383 | $307,506 |
| Revenue | $13,692 | $1,426 | $0 | $0 |
| % Growth | 860.2% | – | – | – |
| Gross Profit | $12,460 | $836 | -$15,891 | $0 |
| % Margin | 91% | 58.6% | – | – |
| EBITDA | -$42,199 | -$54,165 | -$54,769 | -$41,191 |
| % Margin | -308.2% | -3,798.4% | – | – |
| Net Income | -$49,482 | -$60,096 | -$52,226 | -$48,509 |
| % Margin | -361.4% | -4,214.3% | – | – |
| EPS Diluted | -0.92 | -1.12 | -1.05 | -0.92 |
| % Growth | 17.9% | -6.7% | -14.1% | – |
| Operating Cash Flow | -$32,681 | -$54,502 | -$40,364 | -$32,681 |
| Capital Expenditures | -$24 | -$290 | $350 | -$127 |
| Free Cash Flow | -$32,705 | -$54,792 | -$40,014 | -$32,808 |